Service Notification: November 2017
Federal DOT Drug Testing Rule Changes
DOT Updates Drug Testing Panel to Include Opioids
Effective January 1, 2018 — The Federal Department of Transportation (DOT) is amending its drug testing program regulation to include detection for four opioids: hydrocodone, hydromorphone, oxymorphone, and oxycodone. In addition, methylenedioxyamphetamine has been added as an initial test analyte, and methylenedioxyethylamphetamine has been removed as a confirmatory test analyte.
Federally Regulated DOT Drug Test Programs
Mandated changes will take effect January 1, 2018, and apply to all Federally regulated DOT drug test programs. The regulations now harmonize testing with the Department of Health and Human Services (HHS) Mandatory Guidelines that were revised earlier this year. In addition to changes to the DOT urine drug testing panel, the ruling clarifies existing drug testing program provisions, definitions, and technical amendments.
The addition of hydrocodone, hydromorphone, oxymorphone, and oxycodone to the drug panel is in response to the current opioid crisis. Some common names for these semi-synthetic opioids include OxyContin®, Opana®, Percodan®, Percocet®, Vicodin®, Lortab®, Norco®, Dilaudid®, and Exalgo®.
No Action Required
There are no changes required at this time. Please continue to use existing forms to order your DOT drug test services. Prior to the effective date, Alere will automatically update accounts with a new panel that conforms with mandated changes. We will also ensure your organization receives the necessary resources, information, and support services.
If you have questions or would like to enhance your drug test program, please contact your sales or client services representative at 800.433.3823.
Special Alert on DOT Rule Changes
November 29, 2017, 2 p.m. EST
Register via WebEx
Final Rule, Federal Register – DOT Rules and Regulations (11/13/17)
Part 40 Final Rule - DOT Summary of Changes:
Changes at a Glance
- The final rule for DOT drug testing takes effect Jan. 1, 2018
- Adds four semi-synthetic opioids: hydrocodone, oxycodone, hydromorphone; oxymorphone to the DOT testing panel
- Add MDA as an initial test analyte
- Remove testing for MDEA